Candonilimab

Generic Name: Candonilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2394841-59-7

Unique Ingredient Identifier: 6FYG1DS4NW

Background: Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

Indication: 用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Phase 1

Conditions: Advanced Malignant Tumors

Interventions: Drug: AK104
Drug: AK117
Drug: Paclitaxel
Drug: Capecitabine tablets
Drug: Cisplatin
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Docetaxel
Drug: 5-FU

First Posted Date: 2022-02-11

Last Posted Date: 2022-08-11

Lead Sponsor: Akeso

Target Recruit Count: 130

Registration Number: NCT05235542

Locations: 🇨🇳
Shanghai Renji Hospital, Shanghai, China

A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

Phase 3

Active, not recruiting

Conditions: Locally Advanced Cervical Carcinoma

Interventions: Drug: AK104
Radiation: EBRT
Radiation: BT
Drug: cisplatin
Drug: Placebo

First Posted Date: 2022-02-11

Last Posted Date: 2024-08-13

Lead Sponsor: Akeso

Target Recruit Count: 636

Registration Number: NCT05235516

Locations: 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Guizhou Cancer Hospital, Guiyang, Guizhou, China

and more 6 locations

AK104 in Neoadjuvant Treatment of Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

Interventions: Drug: AK104

First Posted Date: 2022-02-07

Last Posted Date: 2024-11-01

Lead Sponsor: Akeso

Target Recruit Count: 14

Registration Number: NCT05227651

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hanzhong, Zhejiang, China

A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

Phase 2

Conditions: Advanced Non-small Cell Lung Cancer

Interventions: Drug: AK104
Drug: Docetaxel

First Posted Date: 2022-01-31

Last Posted Date: 2022-04-01

Lead Sponsor: Akeso

Target Recruit Count: 40

Registration Number: NCT05215067

Locations: 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Phase 2

Active, not recruiting

Conditions: Carcinomas
Cervix Cancer
Cervical Cancer

Interventions: Drug: AK104

First Posted Date: 2021-10-01

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT05063916

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Early Phase 1

Active, not recruiting

Conditions: Advanced or Metastatic Solid Tumours

Interventions: Drug: AK127
Drug: AK104

First Posted Date: 2021-08-25

Last Posted Date: 2024-11-25

Lead Sponsor: Akesobio Australia Pty Ltd

Target Recruit Count: 66

Registration Number: NCT05021120

Locations: 🇦🇺
Ashford Cancer Centre Research, Adelaide, Australia
🇦🇺
Austin Health, Melbourne, Australia
🇦🇺
Monash Health, Melbourne, Australia

and more 2 locations

A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Phase 3

Active, not recruiting

Conditions: Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma

Interventions: Drug: Placebo
Drug: AK104

First Posted Date: 2021-08-17

Last Posted Date: 2024-04-03

Lead Sponsor: Akeso

Target Recruit Count: 610

Registration Number: NCT05008783

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳
The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou, Zhejiang, China
🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China

and more 4 locations

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Phase 2

Conditions: MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Interventions: Drug: AK104

First Posted Date: 2020-09-21

Last Posted Date: 2020-09-21

Lead Sponsor: Peking University

Target Recruit Count: 29

Registration Number: NCT04556253

A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

Phase 2

Terminated

Conditions: MSI-H/dMMR Solid Tumor

Interventions: Drug: AK104

First Posted Date: 2020-09-14

Last Posted Date: 2022-10-19

Lead Sponsor: Akeso

Target Recruit Count: 6

Registration Number: NCT04547101

Locations: 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Biological: AK104

First Posted Date: 2020-01-07

Last Posted Date: 2022-10-12

Lead Sponsor: Akeso

Target Recruit Count: 34

Registration Number: NCT04220307

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy